HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Targher, G. Articles by Falezza, G. Search for Related Content PubMed PubMed Citation Articles by Targher, G. Articles by Falezza, G. Social Bookmarking                What's this?

Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients

¹ Division of Internal Medicine and Diabetes Unity, "Sacro Cuore" Hospital of Negrar, Negrar, Verona, Italy
² Department of Radiology, "Sacro Cuore" Hospital of Negrar, Negrar, Verona, Italy

Nonalcoholic fatty liver disease (NAFLD) is closely correlated to several metabolic syndrome features. We assessed prospectively whether NAFLD predicts future cardiovascular disease (CVD) events among type 2 diabetic individuals, independent of metabolic syndrome features and other classical risk factors. We carried out a prospective nested case-control study in 2,103 type 2 diabetic patients who were free of diagnosed CVD at baseline. During 5 years of follow-up, 248 participants (case subjects) subsequently developed nonfatal coronary heart disease (myocardial infarction and coronary revascularization procedures), ischemic stroke, or cardiovascular death. Using risk-set sampling, 496 patients (control subjects) among those who remained free of diagnosed CVD during follow-up were randomly selected in a 2:1 ratio, matched for age and sex to the case subjects. After adjustment for age, sex, smoking history, diabetes duration, HbA_1c, LDL cholesterol, liver enzymes, and use of medications, the presence of NAFLD was significantly associated with an increased CVD risk (odds ratio 1.84, 95% CI 1.4–2.1, P < 0.001). Additional adjustment for the metabolic syndrome (as defined by National Cholesterol Education Program Adult Treatment Panel III criteria) appreciably attenuated, but did not abolish, this association (1.53, 1.1–1.7, P = 0.02). In conclusion, NAFLD is significantly associated with a moderately increased CVD risk among type 2 diabetic individuals. This relationship is independent of classical risk factors and is only partly explained by occurrence of metabolic syndrome.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATP III, Adult Treatment Panel III; CHD, coronary heart disease; CVD, cardiovascular disease; GGT, -glutamyltransferase; NAFLD, nonalcoholic fatty liver disease

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Stefan, K. Kantartzis, and H.-U. Haring Cardiorespiratory Fitness, Adiposity, and Mortality JAMA, March 5, 2008; 299(9): 1013 - 1014. [Full Text] [PDF]

				G. Targher, L. Bertolini, S. Rodella, R. Tessari, L. Zenari, G. Lippi, and G. Arcaro Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients Diabetes Care, August 1, 2007; 30(8): 2119 - 2121. [Full Text] [PDF]

				G. Targher, L. Bertolini, L. Scala, L. Zenari, G. Lippi, M. Franchini, and G. Arcaro Plasma PAI-1 Levels Are Increased in Patients With Nonalcoholic Steatohepatitis Diabetes Care, May 1, 2007; 30(5): e31 - e32. [Full Text] [PDF]

				G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, and G. Arcaro Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients Diabetes Care, May 1, 2007; 30(5): 1212 - 1218. [Abstract] [Full Text] [PDF]

				K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]

				R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K. E. J. Airaksinen, J. Knuuti, R. Parkkola, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E282 - E290. [Abstract] [Full Text] [PDF]

				G. Targher, L. Bertolini, R. Padovani, S. Rodella, G. Zoppini, L. Zenari, M. Cigolini, G. Falezza, and G. Arcaro Relations Between Carotid Artery Wall Thickness and Liver Histology in Subjects With Nonalcoholic Fatty Liver Disease. Diabetes Care, June 1, 2006; 29(6): 1325 - 1330. [Abstract] [Full Text] [PDF]

				G. Targher, L. Bertolini, R. Tessari, L. Zenari, and G. Arcaro Retinopathy Predicts Future Cardiovascular Events Among Type 2 Diabetic Patients: The Valpolicella Heart Diabetes Study Diabetes Care, May 1, 2006; 29(5): 1178 - 1178. [Full Text] [PDF]